Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma

Clinical and Experimental Dermatology

Volumn 32, Issue 5, 2007, Pages 541-549

  Lee, J R ^a   Shin, J H ^b   Park, J H ^c   Song, S U ^b   Choi, G S ^b  

^a Gachon University College of Medicine   (South Korea)

^b Inha University Hospital   (South Korea)

^c LGE Advanced Research Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CELL MATURATION; CELL THERAPY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; ERADICATION THERAPY; EX VIVO STUDY; FEMALE; HISTOCHEMISTRY; IMMUNITY; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRALESIONAL; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS;

EID: 34547733428     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02453.x     Document Type: Article

References (25)

1. Nestle FO. Vaccines and melanoma. Clin Exp Dermatol 2002 27 : 597 601.
2. Carbone FR, Kurts C, Bennett SR et al. Cross-presentation. a general mechanism for CTL immunity and tolerance. Immunol Today 1998 19 : 368 73.
3. Grabbe S, Beissert S, Schwarz T et al. Dendritic cells as initiators of tumour immune responses: a possible strategy for tumour immunotherapy?. Immunol Today 1995 16 : 117 21.
4. Gabrilovich DI, Nadaf S, Corak J et al. Dendritic cells in antitumour immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumour-bearing mice, are effective antigen carriers in the therapy of established tumours. Cell Immunol 1996 170 : 111 19.
5. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveilance to tumour escape. Nat Immunol 2002 3 : 991 8.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 392 : 245 52.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991 9 : 271 96.
8. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumour immunity. J Exp Med 1996 183 : 283 7.
9. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat Med 1998 4 : 328 32.
10. Boczkowski D, Nair SK, Snyder D et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996 184 : 465 72.
11. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000 18 : 767 811.
12. Jego G, Palucka AK, Blanck JP et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003 19 : 225 34.
13. Scheding S, Kratz-Albers K, Meister B et al. Ex vivo expansion of hematopoietic progenitor cells for clinical use. Semin Hematol 1998 35 : 232 40.
14. Brossart P, Wirths S, Brugger W et al. Dendritic cells in cancer vaccines. Exp Hematol 2001 29 : 1247 55.
15. Schuler G, Schulder-Thurner B et al. The use of dendritic cells in caner immunotherapy. Curr Opin Immunol 2003 15 : 138 47.
16. Mellroy D, Gregoire M. Optimizing dendritic cell-based antitumour immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 2003 52 : 583 91.
17. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002 27 : 571.
18. Schon MP, Schon M, Klotz K. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 2006 126 : 1338 47.
19. Suzuki H, Wang B, Shivji GM et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000 114 : 135 41.
20. In SG, Lee JR, Choi GS et al. The effect of 5% imiquimod cream on C57BL/6 mouse melanoma growth. Kor J Dermatol 2005 43 : 1332 6.
21. Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003 171 : 6275 82.
22. Shackleton M, Davis ID, Hopkin W et al. The impact of imiquimod, a toll-like receptor 7 ligand (TLR7), on the immnuogenicity of melanoma peptide vaccination with adjuvant FLT3 ligand. Cancer Immunity 2004 4 : 9 (online).
23. Palmara F, Meindl S, Holemann M et al. Identification and characterization of pDC-like cells in normal mouse skin and melanoma treated imiquimod. J Immunol 2004 173 : 3051 61.
24. Urosevic M, Dummer R, Conrad C et al. Disease-independent skin recruitment and activation of plamacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005 97 : 1143 53.
25. Mohty M, Vialle-Castello A, Nunes JA et al. IFN-α skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol 2003 171 : 3385 93.